BDXNYSEhealth care

Becton, Dickinson and Company

$153.83上涨+1.89 (+1.24%)

研究复核截至: 2026年7月12日上午12:00 [UTC]

研究概览

Becton, Dickinson and Company operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

開盤: 152.56
最高: 154.93
最低: 152.00
市值: 423.86億
本益比: 26.85
52 週高點: --
股息: 2.760%
季度股利金額: --

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景: A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. The base case remains conditional on separation complexity staying manageable.
多头情景: A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies. New pharmacy automation, microbiology and interventional products can improve mix and customer workflows. A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.
空头情景: Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits. Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs. Provider labor and capital constraints can delay equipment upgrades and pressure pricing.
论点失效条件

关键催化剂

Recurring clinical supplies
A broad installed base supports repeat demand for needles, syringes, diagnostic consumables and medication-management supplies.
Innovation pipeline
New pharmacy automation, microbiology and interventional products can improve mix and customer workflows.
Portfolio separation
A focused separation can simplify the remaining business and sharpen capital allocation if executed cleanly.

主要风险

Separation complexity
Carve-out costs, stranded overhead and operational disruption could dilute expected portfolio benefits.
Quality and regulatory risk
Medical-device recalls, remediation or regulatory findings can interrupt supply and raise costs.
Hospital budget pressure
Provider labor and capital constraints can delay equipment upgrades and pressure pricing.

估值解读

Recurring consumables support defensiveness, but the quality discount narrows only with consistent execution and product reliability.
Separation value should be assessed net of stranded costs, transition spending and the loss of diversification.